Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 28Lung Neoplasms 8Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Neoplasms 5Uterine Cervical Neoplasms 4Recurrence 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Carcinoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Thoracic Neoplasms 1Stomach Neoplasms 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Nonhematologic Malignancies 1Non-Squamous Non-Small Cell Lung Cancer 1Non - Small Cell Lung Cancer NSCLC 1Neuroendocrine Tumors 1NSCLC 1Metatropic dwarfism 1Metastatic HER2-positive Breast Cancer 1Lung Diseases 1Lethal Congenital Contracture Syndrome 2 1HR+HER2- Breast Cancer 1HER2-positive Advanced Breast Cancer 1Desmoplastic Small Round Cell Tumor 1

Interventions

Cisplatin 5Etoposide 4Pemetrexed 3Carboplatin 3pembrolizumab 2belinostat 2RRx-001 2vosaroxin 1taxane 1sagopilone 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1atezolizumab 1abiraterone 1Vinorelbine 1Rhenium 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1PT-100 dipeptide 1PM 01183 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Gemcitabine 1GSK2879552 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Small Cell × Vinorelbine × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡